Peer-Reviewed Medical & Scientific Research, Open to the World

Its published work so far comes mainly from gastroenterology and hepatology, neurology, immunology, and diabetes and endocrinology, with smaller groups of papers in cardiology, surgery and orthopaedics, dentistry and maxillofacial research, and nursing and medical education. TJOCM publishes original clinical studies, narrative reviews, case reports and case series. Recent examples include a real-world evaluation of a diosmectite-based device for diarrhoea, a longitudinal multiomics study of cerebrospinal fluid in cognitive impairment, a national multicentre cohort on chronic kidney disease progression after SARS-CoV-2 infection, and a case series on myasthenia gravis. The journal is a good fit for clinicians who want to report what they observe in everyday practice — an unusual presentation, an audit of a ward population or an evaluation of a teaching method — as well as for formal observational studies. Manuscripts are assessed by double-blind peer review. Articles are published open access under a CC BY 4.0 licence, with copyright kept by the authors. The journal follows COPE ethical principles and is committed to transparency and integrity. An article-processing charge applies on acceptance, with waivers and discounts available to ensure equitable access to publication.

Advances scholarship across the full spectrum of cardiology and cardiovascular medicine, from molecular mechanisms of atherosclerosis to evidence that shapes bedside practice. JOCD welcomes original research, systematic reviews and meta-analyses, clinical case reports, and editorials spanning heart failure, coronary artery disease, myocardial infarction, arrhythmia and electrophysiology, interventional and surgical cardiology, preventive cardiology, lipid disorders, and cardiac rehabilitation. We encourage translational work connecting biomechanics, imaging, pharmacotherapy, and exercise therapy to measurable patient outcomes. Every submission undergoes rigorous double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and each article receives a permanent Crossref DOI. Content is discoverable through OpenAlex and Google Scholar and exposed via an OAI-PMH endpoint for harvesting. The journal follows COPE ethical principles and applies an article-processing charge on acceptance, with waivers and discounts available to ensure equitable access for all authors.

Dedicated to advancing clinical, translational, and surgical cancer research. The journal serves oncologists, hematologists, surgical and radiation oncologists, cancer biologists, and translational scientists with rigorous, internationally accessible scholarship across the cancer continuum, from molecular pathogenesis to diagnosis, treatment, and survivorship. We welcome original research, systematic reviews and meta-analyses, case reports, and editorials spanning tumor biology, cancer biomarkers and liquid biopsy (circulating tumor DNA, cell-free DNA, microRNAs), molecular cytogenetics, hematological malignancies (multiple myeloma, DLBCL and other lymphomas), surgical and interventional oncology, pediatric oncology, translational pharmacology including phytochemical and inflammasome research, and emerging artificial intelligence applications in cancer screening and diagnostics. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, and each is assigned a permanent Crossref DOI. Content is discoverable through OpenAlex and Google Scholar and exposed via an OAI-PMH endpoint for harvesting. The journal adheres to COPE ethical principles and supports global research equity through article-processing-charge waivers and discounts, ensuring authors from all regions can disseminate high-impact cancer research to a worldwide readership.

Advances scholarship across epidemiology, infectious disease and immunization, health policy and systems, environmental and occupational health, and maternal, child and behavioral health, serving researchers, clinicians, epidemiologists, and policymakers worldwide. TAJOPH publishes original research, systematic and narrative reviews, case reports, short communications, and editorials. We particularly welcome work on disease surveillance, vaccine confidence and immunization, antimicrobial resistance, non-communicable disease prevention, social determinants of health, and the population-level lessons of COVID-19 and other public health emergencies. Emphasis is placed on methodological rigor and translational relevance, from quantitative epidemiology and risk-prediction modeling to qualitative and health-systems research that informs policy and practice across high-, middle-, and low-resource settings. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) license with authors retaining copyright, are assigned a permanent Crossref DOI, and are made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint. The journal follows COPE ethical principles, with article-processing charges applied on acceptance and waivers available.

Dedicated to the molecular, cellular, clinical and computational study of the immune system. It publishes original research, reviews, case reports and editorials spanning innate and adaptive immunity, autoimmunity and autoantibodies, tumor immunology and immunotherapy, infection and host defense, and the cytokine and chemokine networks that coordinate immune responses. The journal welcomes work on immune cell biology, neutrophil extracellular traps, antibody and receptor signaling, vaccine immunology, and inflammation, as well as studies in viral infection (including SARS-CoV-2 and post-COVID immunopathology), tuberculosis, and hepatitis. We encourage translational and methodological contributions, including immunology bioinformatics, Mendelian randomization of immune cell traits, and biomarker discovery using clinical and laboratory data. Intended for immunologists, clinician-scientists, oncologists, infectious-disease researchers and laboratory investigators worldwide, the journal bridges bench and bedside. Every submission undergoes double-blind peer review; accepted articles are published under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar and an OAI-PMH endpoint. Editorial practice follows COPE principles.

Dedicated to clinical and translational scholarship across the breadth of urology. The journal serves urologists, surgeons, residents, and researchers by disseminating rigorous work on endourology and stone disease, uro-oncology, pediatric and congenital urology, reconstructive surgery, andrology, and urinary tract disorders. The journal welcomes original research, systematic reviews, clinical studies, surgical technique reports, and detailed case reports. Topics of core interest include percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery (RIRS), ureteroscopic lithotripsy and ureteric stricture, urolithiasis and pediatric nephrolithiasis, prostate and bladder cancer, testicular pathology, and minimally invasive and reconstructive urological techniques. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and are assigned a permanent Crossref DOI for citability and long-term preservation. Content is discoverable through OpenAlex and Google Scholar and exposed via an OAI-PMH endpoint for harvesting. Guided by COPE ethical principles, Annals of Urology aims to be a trusted, internationally accessible venue that advances urological evidence and practice while offering authors a transparent route to publication, with article-processing charges applied on acceptance and waivers or discounts available on request.